A cutting-edge image analysis platform for higher order OCT analysis successfully extracted novel fluid features and evaluated them for resolution extent and tempo, reported Justis P. Ehlers, MD.
“Current conventional OCT metrics used in most clinical trials are limited to global measures of retina thickness, retinal volume or perhaps manual linear measurements of areas of interest,” said Dr. Ehlers, Norman C. and Donna L. Harbert Endowed Chair of Ophthalmic Research at the Cole Eye Institute, Cleveland Clinic, Cleveland, OH. “New tools for higher-order OCT assessment enables in-depth evaluation of more specific features of interest, such as targeted retinal layers or fluid compartments, and may allow for unique characterization of disease phenotypes and treatment response.”
Dr. Ehlers noted that this is emerging technology.
“Further research is currently ongoing, including for subretinal material and sub-RPE feature extraction and layer-based assessment,” he said. “In addition, subvisual feature and radiomics interrogation of these data-rich images may provide unique insights into disease process and prognosis. Ultimately, these approaches may lead to the identification of imaging biomarkers for predicting optimal response to therapeutics, best dosing regimens, and overall prognosis.”
The novel analysis was applied to OCT scans collected in OSPREY, a 56-week, phase II study comparing brolucizumab (Novartis) and aflibercept (Eylea, Regeneron) for the treatment of neovascular AMD. The study began with a matched treatment period during which both anti-VEGF agents were given as three monthly loading doses and then every eight weeks through week 32.
For the final brolucizumab dosing cycle, the treatment interval was extended to 12 weeks.
RELATED CONTENT: Keys to integrating, interpreting different types of OCT scans
JUSTIS P. EHLERS, MD
E: [email protected]
This article is adapted from Dr. Ehlers’ presentation at the 2019 meeting of the American Society of Retina Specialists. Dr. Ehlers is a consultant to Alcon, Allergan, Allegro, Genentech, Leica, Novartis, Regeneron, Thrombogenics, and Zeiss.